Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Cryofocus Medtech (Shanghai) Co. Ltd. Class H ( (HK:6922) ).
Cryofocus Medtech (Shanghai) Co., Ltd. announced the successful passage of all proposed resolutions during its 2024 Annual General Meeting held on June 20, 2025. The resolutions, which included approving the work reports, profit distribution plan, and financial statements for 2024, as well as the re-appointment of Ernst & Young as auditors, were unanimously approved by shareholders, reflecting strong support for the company’s strategic direction.
More about Cryofocus Medtech (Shanghai) Co. Ltd. Class H
Cryofocus Medtech (Shanghai) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the medical technology industry. The company is listed on the Hong Kong Stock Exchange and focuses on developing innovative medical solutions.
Average Trading Volume: 88,906
Technical Sentiment Signal: Sell
See more insights into 6922 stock on TipRanks’ Stock Analysis page.